Endothelial cell-derived interleukin-6 regulates tumor growth

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Neiva, Kathleen G ^a   Warner, Kristy A ^a   Campos, Marcia S ^a   Zhang, Zhaocheng ^a   Moren, Juliana ^a   Danciu, Theodora E ^a   Nör, Jacques E ^a,b,c,d  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b The Department of Civil and Environmental Engineering   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cervical Cancer; Molecular targeted therapy; Signaling pathways; STAT3

Indexed keywords

INTERLEUKIN 6; RNA; STAT3 PROTEIN; CULTURE MEDIUM; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CAPILLARY DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE SILENCING; GROWTH STIMULATION; HUMAN; HUMAN CELL; HUMAN DERMAL MICROVASCULAR ENDOTHELIUM CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; CULTURE MEDIUM; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHARMACOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE SILENCING; HETEROGRAFTS; HUMANS; INTERLEUKIN-6; MALE; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN;

EID: 84898600615     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-99     Document Type: Article

References (48)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Committee on Practice B-G ACOG practice bulletin. Diagnosis and treatment of cervical carcinomas, number 35, May 2002. Obstet Gynaecol 2002, 99:855-867. Committee on Practice B-G.
3. Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer 1990, 65:2507-2514. 10.1002/1097-0142(19900601)65:11<2507::AID-CNCR2820651120>3.0.CO;2-9, 2337867.
4. Lai CH, Hsueh S, Hong JH, Chang TC, Tseng CJ, Chou HH, Huang KG, Lin JD. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery?. Int J Gynecol Cancer 1999, 9:28-36. 10.1046/j.1525-1438.1999.09895.x, 11240740.
5. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 2000, 78:97-105. 10.1006/gyno.2000.5826, 10926787.
6. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001, 357:1490-1493. 10.1016/S0140-6736(00)04646-8, 11377601.
7. Wang SS, Sherman ME, Hildesheim A, Lacey JV, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004, 100:1035-1044. 10.1002/cncr.20064, 14983500.
8. Sherman ME, Wang SS, Carreon J, Devesa SS. Mortality trends for cervical squamous and adenocarcinoma in the United States. Relation to incidence and survival. Cancer 2005, 103:1258-1264. 10.1002/cncr.20877, 15693030.
9. Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidem Biomarkers Prev 2005, 14:2191-2199.
10. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Nat Cancer Inst 2006, 98:303-315. 10.1093/jnci/djj067, 16507827.
11. Folkman J. Tumor angiogenesis: therapeutic implications. New Eng J Med 1971, 285:1182-1186. 10.1056/NEJM197111182852108, 4938153.
12. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739. 10.1038/nrc905, 12360276.
13. Kerbel RS. Tumor angiogenesis. New Eng J Med 2008, 358:2039-2049. 10.1056/NEJMra0706596, 18463380.
14. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202. 10.1126/science.289.5482.1197, 10947988.
15. Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for therapy. Curr Opinion Chem Biol 2001, 5:308-313.
16. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat 2008, 11:219-230. 10.1016/j.drup.2008.09.001, 18948057.
17. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. New Eng J Med 2004, 351:317-319. 10.1056/NEJMp048143, 15269308.
18. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006, 42:3127-3139. 10.1016/j.ejca.2006.09.015, 17098419.
19. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007, 7:475-485. 10.1038/nrc2152, 17522716.
20. Le Tourneau C, Siu LL. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opinion Oncol 2008, 20:256-263.
21. Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, Hsieh CY. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. Gynecol Oncol 2001, 82:49-56. 10.1006/gyno.2001.6235, 11426961.
22. Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M, Kakuma T. Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Brit J Cancer 2009, 101:967-972. 10.1038/sj.bjc.6605212, 2743356, 19638983.
23. Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 1993, 13:276-288. 358907, 7678052.
24. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene 2003, 22:1517-1527. 10.1038/sj.onc.1206226, 12629515.
25. Kaneko T, Zhang Z, Mantellini MG, Karl E, Zeitlin B, Verhaegen M, Soengas MS, Lingen M, Strieter RM, Nunez G, Nör JE. Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. Cancer Res 2007, 67:9685-9693. 10.1158/0008-5472.CAN-07-1497, 17942898.
26. Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nor JE. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia 2009, 11:583-593. 2685447, 19484147.
27. Nor JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, Addison CL, Mooney DJ, Polverini PJ. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 2001, 81:453-463. 10.1038/labinvest.3780253, 11304564.
28. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, Polverini PJ. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001, 61:2183-2188.
29. Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, Spalding AC, Nor JE. Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia 2008, 10:131-139. 10.1593/neo.07815, 2244688, 18283335.
30. Squarize CH, Castilho RM, Sriuranpong V, Pinto DS, Gutkind JS. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia 2006, 8:733-746. 10.1593/neo.06274, 1584297, 16984731.
31. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, Bromberg JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117:3846-3856. 10.1172/JCI31871, 2096430, 18060032.
32. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007, 117:3988-4002. 10.1172/JCI32533, 2096439, 18060036.
33. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007, 130:691-703. 10.1016/j.cell.2007.06.054, 3010851, 17719546.
34. Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008, 3:1159-1168. 10.1002/cmdc.200800123, 2603136, 18683176.
35. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 2006, 1091:151-169. 10.1196/annals.1378.063, 17341611.
36. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310. 10.1038/sj.onc.1210422, 17496923.
37. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008, 14:342-346. 10.1158/1078-0432.CCR-07-4790, 18223206.
38. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262. 10.1016/S1535-6108(03)00248-4, 14585353.
39. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Rev Cancer 2002, 2:489-501.
40. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest 2008, 118:3003-3006. 2518078, 18725993.
41. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008, 118:3051-3064. 2518074, 18725989.
42. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074. 2518073, 18725988.
43. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 2006, 103:14477-14482. 10.1073/pnas.0606836103, 1599986, 16973750.
44. McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzym Regul 2007, 47:64-103.
45. Kamran MZ, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int. 2013, 2013:421821. 3807846, 24199193.
46. Piperi C, Samaras V, Levidou G, Kavantzas N, Boviatsis E, Petraki K, Grivas A, Barbatis C, Varsos V, Patsouris E, Korkolopoulou P. Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry. Cytokine 2011, 55:387-395. 10.1016/j.cyto.2011.05.012, 21684758.
47. Monk BJ, Willmott LJ, Sumner DA. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 2010, 116:181-186. 10.1016/j.ygyno.2009.09.033, 19861227.
48. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Rev Cancer 2008, 8:592-603.